Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: A post hoc pooled analysis of two clinical studies

Risk Management and Healthcare Policy

Volumn 9, Issue , 2016, Pages 231-241

  Bell, Kelly F ^a   Katz, Arie ^a   Sheehan, John J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Dapagliflozin; Metformin; Quality measures; Type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 84992364817     PISSN: None     EISSN: 11791594     Source Type: Journal    
DOI: 10.2147/RMHP.S108586     Document Type: Article

References (54)

1. American Diabetes Association. Standards of medical care in diabetes-2016. Diabetes Care. 2016;39(Suppl 1):S1-S119.
2. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm -2016 executive summary. Endocr Pract. 2016;22(1):84-113.
3. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States. Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed June 23, 2016.
4. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033-1046.
5. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
6. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068-1083.
7. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl 1):S88-S89.
8. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368(17):1613-1624.
9. DiBonaventura M, Krishnarajah G, Pollack A, Wagner J, Balar B, Graham J. The combined effects of obesity and hypertension on the quality of life, work productivity, and activity impairment of type 2 diabetes patients. Presented at: The Obesity Society; October 8-12, 2010; San Diego, CA.
10. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73(4):327-339.
11. US Department of Health and Human Services. Agency for Healthcare Research and Quality: Tutorials on quality measures. Available from: http://www.qualitymeasures.ahrq.gov/tutorial/index.aspx. Accessed June 6, 2016.
12. O’Connor PJ, Bodkin NL, Fradkin J, et al. Diabetes performance measures: current status and future directions. Diabetes Care. 2011;34(7):1651-1659.
13. US Department of Health and Human Services. Agency for Healthcare Research and Quality. Diabetes mellitus. Available from: http://www.qualitymeasures.ahrq.gov/browse/by-topic-detail.aspx?id=44003&ct=1. Accessed June 1, 2016.
14. Centers for Disease Control and Prevention. National Healthcare Safety Network. NHSN Measures Endorsed by the National Quality Forum (NQF). Available from: http://www.cdc.gov/nhsn/nqf/. Accessed June 20, 2016.
15. National Quality Forum. About Us. Available from: http://www.qualityforum.org/story/About_Us.aspx. Accessed June 6, 2016.
16. National Quality Forum. Maintenance of NQF-Endorsed Performance Measures. Available from: http://www.qualityforum.org/Measuring_Performance/Endorsed_Performance:Measures_Maintenance.aspx. Accessed June 6, 2016.
17. US Department of Health and Human Services. Agency for Healthcare Research and Quality. Measure summary: comprehensive diabetes care: percentage of members 18 to 64 years of age with diabetes (type 1 and type 2) whose most recent hemoglobin A1c (HbA1c) level is less than 7.0% (controlled). Available from: http://www.qualitymeasures.ahrq.gov/content.aspx?id=48628&search=hba1c+%3C7. Accessed June 15, 2016.
18. US Department of Health and Human Services. Agency for Healthcare Research and Quality. Measure summary: diabetes mellitus: percent of patients with blood pressure reading less than 130/80 in the last 12 months. Available from: http://www.qualitymeasures.ahrq.gov/content.aspx?id=27623&search=blood+pressure+%3C130. Accessed June 15, 2016.
19. US Department of Health and Human Services. Agency for Healthcare Research and Quality. Measure summary: diabetes mellitus: percent of patients whose most recent fasting low-density lipoprotein (LDL) was less than 100 (in the last 12 months). Available from: http://www.qualitymeasures.ahrq.gov/content.aspx?id=27624&search=ldl+%3C100. Accessed July 10, 2016.
20. National Quality Forum. Endocrine measures. Comprehensive diabetes care: hemoglobin A1c (HbA1c) control (<8.0%). NQF identifier: 0575. Available from: http://www.qualityforum.org/ProjectMeasures.aspx?projectID=73652. Accessed July 10, 2016.
21. National Quality Forum. Comprehensive diabetes care: hemoglobin A1c (HbA1c) poor control (>9.0%). NQF identifier: 0059. Available from: http://www.qualityforum.org/ProjectMeasures.aspx?projectID=73652. Accessed March 14, 2016.
22. National Quality Forum. Endocrine measures. Comprehensive diabetes care: blood pressure control (<140/90 mm hg). NQF identifier: 0061. Available from: http://www.qualityforum.org/ProjectMeasures.aspx?projectID=73652. Accessed June 1, 2016.
23. National Quality Forum. Endocrine measures. Optimal Diabetes Care (Composite Measure). NQF identifier: 0729. Available from: http://www.qualityforum.org/ProjectMeasures.aspx?projectID=73652. Accessed June 1, 2016.
24. US Department of Health and Human Services. Agency for Healthcare Research and Quality. Diabetes mellitus: percent of patients with a body mass index (BMI) greater than 25 who have lost 10 pounds at any time in the last 12 months. Available from: http://www.qualitymeasures.ahrq.gov/content.aspx?id=27634&search=weight+loss+and+diabetes. Accessed June 7, 2016.
25. Farxiga® (dapagliflozin) [prescribing information]. Wilmington, DE: AstraZeneca; 2015.
26. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-2233.
27. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217-2224.
28. Jabbour SA, Hardy E, Sugg J, Parikh S, Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37(3):740-750.
29. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-2022.
30. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473-1478.
31. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405-415.
32. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-1380.
33. Whaley JM, Tirmenstein M, Reilly TP, et al. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2012;5:135-148.
34. Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med. 2013;125(3): 181-189.
35. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446-456.
36. Centers for Disease Control and Prevention. Division of Nutrition, Physical Activity, and Obesity. About adult BMI. Available from: http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/. Accessed June 7, 2016.
37. Bailey RA, Damaraju CV, Martin SC, Meininger GE, Rupnow MF, Blonde L. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin. Am J Manag Care. 2014;20(1 Suppl):S16-S24.
38. Bailey RA, Vijapurkar U, Meininger G, Rupnow MF, Blonde L. Diabetes-related composite quality end point attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. Clin Ther. 2015;37(5):1045-1054.
39. Bailey RA, Vijapurkar U, Meininger GE, Rupnow MF, Blonde L. Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. Am J Manag Care. 2014;20(13 Suppl):S296-S305.
40. American Diabetes Association. Fast Facts Data and Statistics About Diabetes. Available from: http://professional.diabetes.org/ResourcesFor-Professionals.aspx?cid=91777&loc=dorg-statistics. Accessed June 23, 2016.
41. Kaplan SH, Griffith JL, Price LL, Pawlson LG, Greenfield S. Improving the reliability of physician performance assessment: identifying the “physician effect” on quality and creating composite measures. Med Care. 2009;47(4):378-387.
42. Reeves D, Campbell SM, Adams J, Shekelle PG, Kontopantelis E, Roland MO. Combining multiple indicators of clinical quality: an evaluation of different analytic approaches. Med Care. 2007;45(6):489-496.
43. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253-270.
44. Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves beta cell function. J Clin Endocrinol Metab. 2015;100(5):1927-1932.
45. Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes. 2002;51(Suppl 1):S134-S137.
46. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010;33(2):442-449.
47. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509-514.
48. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499-508.
49. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512-517.
50. Neschen S, Scheerer M, Seelig A, et al. Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice. Diabetes. 2015;64(1):284-290.
51. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542-546.
52. Katz A, Ptaszynska A, Mansfield T, et al. Time course of changes in glycemic parameters and body weight in patients receiving dapagliflozin as add-on or as initial combination therapy with metformin [265-OR]. Diabetes. 2014;63(Suppl 1):A1-A102.
53. Saturni S, Bellini F, Braido F, et al. Randomized controlled trials and real life studies. approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther. 2014;27(2):129-138.
54. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. Criteria for Distinguishing Effectiveness from Efficacy Trials in Systematic Reviews. Technical review 12 (prepared by the RTI-International-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016). AHRQ Publication No. 06-0046. Rockville, MD; 2006.